BSH 2017 | BCR inhibitors improving CLL patient outcomes

John Gribben

John Gribben, MD, DSc, FRCPath, FMed Sci, from Barts Cancer Institute, London, UK discusses the advances in chronic lymphocytic leukemia (CLL) treatment over time. Chemo-immunotherapy was the standard of care for many years; however, the development of resistance resulted in a lack of alternative treatments for patients. There are now solutions for the these patients – those who present with abnormalities in the P53 pathway or those who have a short duration to therapies like chemo-immunotherapy. The introduction of BCR inhibitors, such as ibrutinib and idelalisib, in combination with rituximab, and also venetoclax, are now filling that unmet need. Prof. Gribben tells us about how we are using these treatments. This interview was recorded at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK.
This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

Share this video